The Bipolar Comprehensive Outcomes Study (BCOS): Baseline findings of an Australian cohort study

Journal of Affective Disorders

Volumn 107, Issue 1-3, 2008, Pages 135-144

  Kulkarni, Jayashri ^a   Berk, Michael ^b,d,e   Fitzgerald, Paul B ^a   de Castella, Anthony R ^a   Montgomery, William ^c   Kelin, Katarina ^c   Brnabic, Alan ^c   Granger, Renee E ^c   Dodd, Seetal ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ELI LILLY AUSTRALIA PTY LTD   (Australia)

^d ORYGEN RESEARCH CENTRE   (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Bipolar disorder; Mood stabilizers; Naturalistic design; Non interventional; Observational study; Schizoaffective disorder

Indexed keywords

CARBAMAZEPINE; LITHIUM CARBONATE; MOOD STABILIZER; OLANZAPINE; VALPROIC ACID;

ADULT; ARTICLE; AUSTRALIA; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; FEMALE; HAMILTON SCALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS;

ADULT; AGED; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; AUSTRALIA; BENZODIAZEPINES; BIPOLAR DISORDER; CARBAMAZEPINE; COHORT STUDIES; FEMALE; HEALTH STATUS; HUMANS; LITHIUM CARBONATE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOCIAL ADJUSTMENT; TREATMENT OUTCOME; VALPROIC ACID;

EID: 39649109458     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2007.08.012     Document Type: Article

References (35)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Text Revision: DSM-IV-TR (2000), American Psychiatric Press, Washington, DC
2. Australian Bureau of Statistics. 6302.0 - Average Weekly Earnings, Australia, Aug 2005 [online] (2005). http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/7AFBCF0AA65EB2DACA25711D000DF2B2?opendocument Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/7AFBCF0AA65EB2DACA25711D000DF2B2?opendocument [cited 28 February 2007]
3. Australian Bureau of Statistics. 6202.0 - Labour Force, Australia, Dec 2005 [online] (2006). http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/A549CED11B99DF4ECA25710F006F7F14?opendocument Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/A549CED11B99DF4ECA25710F006F7F14?opendocument [cited 28 February 2007]
4. Australian Bureau of Statistics. 4831.0.55.001 - Tobacco Smoking in Australia: A Snapshot, 2004-05 [online] (2006). http://www.abs.gov.au/Ausstats/abs@.nsf/39433889d406eeb9ca2570610019e9a5/8b2eb904c4e70609ca2571e9001cad09!OpenDocument Available from: http://www.abs.gov.au/Ausstats/abs@.nsf/39433889d406eeb9ca2570610019e9a5/8b2eb904c4e70609ca2571e9001cad09!OpenDocument [cited 28 February 2007]
5. Australian Institute of Health and Welfare. National Drug Strategy Household Survey - detailed findings. Drug Statistics Series vol. 16 (2005), Department of Health and Ageing, Canberra 1-142
6. Bauer M.S., Kirk G., Gavin C., and Williford W. Correlates of functional and economic outcome in bipolar disorder: a prospective study. J. Affect. Disord. 65 (2001) 231-241
7. Collaborative Working Group on Clinical Trial Evaluation. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations. J. Clin. Psychiatry 59 Suppl 12 (1998) 10-16
8. Coryell W., Scheftner W., Keller M., Endicott J., Maser J., and Klerman G.L. The enduring psychosocial consequences of mania and depression. Am. J. Psychiatry 150 (1993) 720-727
9. EuroQoL Group. EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy vol. 16 (1990) 199-208
10. Goetz I., Tohen M., Reed C., Lorenzo M., and Vieta E. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord. 9 (2007) 45-52
11. Goldberg J.F., and Harrow M. Subjective life satisfaction and objective functional outcome in bipolar and unipolar mood disorders: a longitudinal analysis. J. Affect. Disord. 89 (2005) 79-89
12. Gomez J.C., Sacristan J.A., Hernandez J., Breier A., Ruiz C.P., Anton S.C., and Fontova C.E. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic study of olanzapine in schizophrenia. J. Clin. Psychiatry, 61 (2000) 335-343
13. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
14. Harris E.C., and Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry 170 (1997) 205-228
15. Jablensky A., McGrath J., Herrman H., Castle D., Gureje O., Morgan V., and Korten V. Diagnostic Interview for Psychosis (Interview Schedule Version 1.0, National Survey of Mental Health and Wellbeing Report 4: people living with psychotic illness: An Australian study 1997-98) (1999), Commonwealth Department of Health and Aged Care, Canberra
16. Katz M.M., Secunda S.K., Hirschfeld R.M.A., and Koslow S.H. NIMH clinical research branch collaborative program on the psychobiology of depression. Arch. Gen. Psychiatry 36 (1979) 765-771
17. Keller M.B., Lavori P.W., Friedman B., Nielsen E., Endicott J., McDonald-Scott P., and Andreasen N.C. The longitudinal interval follow-up evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch. Gen. Psychiatry 44 (1987) 540-548
18. Kogan J.N., Otto M.W., Bauer M.S., Dennehy E.B., Miklowitz D.J., Zhang H.W., Ketter T., Rudorfer M.V., Wisniewski S.R., Thase M.E., Calabrese J., and Sachs G.S. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disord. 6 (2004) 460-469
19. Lara D.R., Pinto O., Akiskal K., and Akiskal H.S. Toward an integrative model of the spectrum of mood, behavioral and personality disorders based on fear and anger traits: I. Clinical implications. J. Affect. Disord. 94 (2006) 67-87
20. Leidy N.K., Palmer C., Murray M., Robb J., and Revicki D.A. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder. Psychometric performance of four self-report measures. J. Affect. Disord. 48 (1998) 207-214
21. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 13 (1998) 1-7
22. Malhi G.S., and Berk M. Pharmacotherapy of bipolar disorder: the role of atypical antipsychotics and experimental strategies. Hum. Psychopharmacol. 17 (2002) 407-412
23. Mantere O., Suominen K., Leppamaki S., Valtonen H., Arvilommi P., and Isometsa E. The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi Bipolar Study (JoBS). Bipolar Disord. 6 (2004) 395-405
24. Maremmani I., Perugi G., Pacini M., and Akiskal H.S. Toward a unitary perspective on the bipolar spectrum and substance abuse: Opiate addiction as a paradigm. J. Affect. Disord. 93 (2006) 1-12
25. Mitchell J.D., Brown E.S., and Rush A.J. Comorbid disorders in patients with bipolar disorder and concomitant substance dependence. J. Affect. Disord. 102 (2007) 281-287
26. Morris C.D., Giese A.A., Turnbull J.J., Dickinson M., and Johnson-Nagel N. Predictors of tobacco use among persons with mental illnesses in a statewide population. Psychiatr. Serv. 57 (2006) 1035-1038
27. Robb J.C., Young L.T., Cooke R.G., and Joffe R.T. Gender differences in patients with bipolar disorder influence outcome in the medical outcomes survey (SF-20) subscale scores. J. Affect. Disord. 49 (1998) 189-193
28. Rush A.J., Crismon M.L., Kashner T.M., Toprac M.G., Carmody T.J., Trivedi M.H., Suppes T., Miller A.L., Biggs M.M., Shores-Wilson K., Witte B.P., Shon S.P., Rago W.V., Altshuler K.Z., and TMAP Research Group. Texas Medication Algorithm Project, Phase 3 (TMAP-3): rationale and study design. J. Clin. Psychiatry 64 (2003) 357-369
29. Schillevoort I., de Boer A., Herings R.M., Roos R.A., Jansen P.A., and Leufkens H.G. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann. Pharmacother. 35 (2001) 1517-1522
30. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., and Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 (1998) 22-33
31. Spearing M.K., Post R.M., Leverich G.S., Brandt D., and Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73 (1997) 159-171
32. Suppes T., Leverich G.S., Keck P.E., Nolen W.A., Denicoff K.D., Altshuler L.L., McElroy S.L., Rush A.J., Kupka R., Frye M.A., Bickel M., and Post R.M. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J. Affect. Disord. 67 (2001) 45-59
33. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30 (1992) 473-483
34. Weissman M.M., Bland R.C., Canino G.J., Faravelli C., Greenwald S., Hwu H.G., Joyce P.R., Karam E.G., Lee C.K., Lellouch J., Lepine J.P., Newman S.C., Rubio-Stipec M., Wells J.E., Wickramaratne P.J., Wittchen H., and Yeh E.K. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276 (1996) 293-299
35. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978) 429-435